Xenetic Biosciences (NASDAQ:XBIO) Issues Quarterly Earnings Results, Meets Expectations

Xenetic Biosciences (NASDAQ:XBIO) issued its earnings results on Tuesday. The company reported ($0.83) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.83), Zacks reports. Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $0.54 million.

Xenetic Biosciences Stock Performance

Shares of Xenetic Biosciences stock traded down $0.14 on Thursday, hitting $3.15. 59,989 shares of the company’s stock were exchanged, compared to its average volume of 7,299. The company has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $3.98. The stock has a market capitalization of $4.85 million, a PE ratio of -1.08 and a beta of 2.29. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.97.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.